AVBP Insider Trading Activity and SEC Form 4 Filings
AVBP insider trading summary
Over the past 12 months, insiders at ArriVent BioPharma, Inc. (AVBP) reported 2 sales worth $26.0M by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $26.0M.
Latest AVBP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 10, 2025 | Hillhouse Investment Management, Ltd. | 10% Owner | Sell | $13.0M (555,555 @ $23.37) |
| Dec 10, 2025 | Hhlr Advisors, Ltd. | 10% Owner | Sell | $13.0M (555,555 @ $23.37) |
| Jan 30, 2024 | OrbiMed Capital GP VIII LLC | Director | Buy | $4.0M (222,222 @ $18.00) |
| Jan 30, 2024 | OrbiMed Asia GP IV, L.P. | Director | Buy | $4.0M (222,222 @ $18.00) |
| Jan 30, 2024 | James Healy | Director | Buy | $8.0M (444,444 @ $18.00) |
| Jan 30, 2024 | OrbiMed Advisors IV Ltd | Director | Buy | $4.0M (222,222 @ $18.00) |
| Jan 30, 2024 | Hillhouse Investment Management, Ltd. | 10% Owner | Buy | $10.0M (555,555 @ $18.00) |
| Jan 30, 2024 | Hhlr Advisors, Ltd. | 10% Owner | Buy | $10.0M (555,555 @ $18.00) |
| Jan 30, 2024 | Carl L Gordon | Director | Buy | $4.0M (222,222 @ $18.00) |
| Jan 30, 2024 | Orbimed Advisors LLC | Director | Buy | $4.0M (222,222 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.